Blog
RSS FeedPosted by Michael Wonder on 21 Jun 2023
Darolutamide in combination with androgen deprivation therapy and docetaxel for the treatment of patients with hormone-sensitive metastatic prostate cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of darolutamide (Nubeqa) in combination with androgen ...
Posted by Michael Wonder on 20 Jun 2023
Cemiplimab for the treatment of patients with recurrent or metastatic cervical cancer
20 June 2023 - NICE is unable to make a recommendation on the use of cemiplimab (Libtayo) for the treatment of ...
Posted by Michael Wonder on 14 Jun 2023
Dabrafenib mesylate and trametinib dimethyl sulphoxide for the treatment of patients with advanced BRAF V600 mutation positive non-small-cell lung cancer
14 June 2023 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Tafinlar) and trametinib dimethyl ...
Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
7 June 2023 - NICE has published final evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
7 June 2023 - NICE has published final evidence-based recommendations on the use of brexucabtagene autoleucel (Tecartus) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma
7 June 2023 - NICE has published evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment of ...
Posted by Michael Wonder on 06 Jun 2023
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
6 June 2023 - NICE has published evidence-based recommendations for daratumumab (Darzalex) for use in combination with bortezomib and dexamethasone ...
Posted by Michael Wonder on 02 Jun 2023
Mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma
31 May 2023 - NICE has published evidence based recommendations on the use of mosunetuzumab (Lunsumio) for the treatment of ...
Posted by Michael Wonder on 31 May 2023
Ibrutinib and venetoclax for untreated chronic lymphocytic leukaemia
31 May 2023 - NICE has published evidence-based recommendations on the use of ibrutinib (Imbruvica) in combination with venetoclax (Venclyxto) ...
Posted by Michael Wonder on 30 May 2023
Family seek to raise money for lung cancer drug
29 May 2023 - A family has raised £12,000 to pay for a cancer drug for their mother, which was ...
Posted by Michael Wonder on 23 May 2023
Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
22 May 2023 - More than 47,000 new cases of prostate cancer are diagnosed every year in England. ...
Posted by Michael Wonder on 17 May 2023
Ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma
17 May 2023 - NICE is unable to make a recommendation on the use of ciltacabtagene autoleucel (Carvykti) for the treatment ...
Posted by Michael Wonder on 10 May 2023
Olaparib for previously treated BRCA mutation positive hormone-relapsed metastatic prostate cancer
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate ...
Posted by Michael Wonder on 10 May 2023
Olaparib for adjuvant treatment of BRCA mutation positive HER2 negative high-risk early breast cancer after chemotherapy
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation positive HER2 ...
Posted by Michael Wonder on 09 May 2023
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies
9 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using belantamab ...